Bio-Images Research partners Oxthera in £1.9m primary hyperoxaluria project
Two-year project includes EU and US partners and is funded by £1.9m FP7 grant
Glasgow-based clinical research expert Bio-Images Research is a partner in a new EU drug development project called ELIMOX, which is focusing on a treatment for the genetic condition Primary Hyperoxaluria (PH).
The two-year project, funded by a £1.9m FP7 grant and co-ordinated by Swedish biopharmaceutical firm OxThera, will incorporate 10 additional partners from across Europe and North America with the aim of developing a unique bacterial pharmaceutical product for the treatment of PH.
The ELIMOX project will perform drug development, analytical methods development and clinical development for PH. The bacteria, Oxalobacter formigenes, has been shown to actively promote enteric elimination of oxalate in animal models and early clinical studies evaluating an initial formulation of the bacteria showed a substantial decrease in urinary oxalate excretion in subjects with PH.
'The research findings from this project will add profound knowledge relating to the impact of probiotic pharmaceutical treatments,' commented Elisabeth Lindner, CEO of OxThera and co-ordinator of the ELIMOX project.
